BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16188904)

  • 1. Hypercalcaemia induced by excessive parathyroid hormone secretion in a patient with a neuroendocrine tumour.
    Vacher-Coponat H; Opris A; Denizot A; Dussol B; Berland Y
    Nephrol Dial Transplant; 2005 Dec; 20(12):2832-5. PubMed ID: 16188904
    [No Abstract]   [Full Text] [Related]  

  • 2. PTHrP, calcitonin and calcitriol in a case of severe, protracted and refractory hypercalcemia due to a pancreatic neuroendocrine tumor.
    Van den Eynden GG; Neyret A; Fumey G; Rizk-Rabin M; Vermeulen PB; Bouizar Z; Body JJ; Dirix LY
    Bone; 2007 Apr; 40(4):1166-71. PubMed ID: 17188588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protracted hypocalcaemia following a single dose of denosumab in humoral hypercalcaemia of malignancy due to PTHrP-secreting neuroendocrine tumour.
    Teng J; Abell S; Hicks RJ; Hofman MS; Sachithanandan N; McKelvie P; MacIsaac RJ
    Clin Endocrinol (Oxf); 2014 Dec; 81(6):940-2. PubMed ID: 24890549
    [No Abstract]   [Full Text] [Related]  

  • 4. Parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumours: case series and literature review.
    Srirajaskanthan R; McStay M; Toumpanakis C; Meyer T; Caplin ME
    Neuroendocrinology; 2009; 89(1):48-55. PubMed ID: 18679021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report of multimodality treatment for metastatic parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumour.
    Rossi RE; Naik K; Navalkissoor S; Imber C; O'Beirne J; Toumpanakis C; Caplin ME
    Tumori; 2014; 100(4):153e-6e. PubMed ID: 25296608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parathyroid hormone-related protein in pancreatic exocrine cancer associated with hypercalcaemia.
    Bandyopadhyay P; Baksi S; Bandyopadhyay D; Patel CU
    Int J Clin Pract; 2003 Mar; 57(2):140-2. PubMed ID: 12661799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe hypercalcaemia from secretion of parathyroid hormone-related peptide.
    Barakat MT; Ashrafian H; Todd JF; Meeran K; Williams GR
    Lancet Oncol; 2004 Oct; 5(10):633-5. PubMed ID: 15465467
    [No Abstract]   [Full Text] [Related]  

  • 8. A calcitonin-secreting tumor of the pancreas.
    Iacobone M
    Dig Surg; 2005; 22(1-2):114. PubMed ID: 15849474
    [No Abstract]   [Full Text] [Related]  

  • 9. Pancreatic neuroendocrine tumor with extensive vascularisation and parathyroid hormone-related protein (PTHrP)--associated hypercalcemia of malignancy.
    Clemens P; Gregor M; Lamberts R
    Exp Clin Endocrinol Diabetes; 2001; 109(7):378-85. PubMed ID: 11573150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parathyroid hormone related protein (PTHrP) mediated hypercalcaemia complicating enteropancreatic malignancy in multiple endocrine neoplasia type 1 (MEN 1).
    Burgess JR; Wilkinson S; Lowenthal RM
    Aust N Z J Med; 2000 Apr; 30(2):280-1. PubMed ID: 10833127
    [No Abstract]   [Full Text] [Related]  

  • 11. Pancreatic islet-cell neoplasia, with secretion of a parathormone-like substance and hypercalcemia.
    Vair DB; Boudreau SF; Reid EL
    Can J Surg; 1987 Mar; 30(2):108-10. PubMed ID: 3030525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ectopic luteinizing hormone secretion and anovulation.
    Hirshberg B; Conn PM; Uwaifo GI; Blauer KL; Clark BD; Nieman LK
    N Engl J Med; 2003 Jan; 348(4):312-7. PubMed ID: 12540644
    [No Abstract]   [Full Text] [Related]  

  • 13. Malignant hypercalcaemia related to parathyroid hormone-related peptide (PTHrP) secretion from a metastatic pancreatic neuroendocrine tumour (NET).
    Symington M; Davies L; Kaltsas G; Weickert MO
    BMJ Case Rep; 2017 Mar; 2017():. PubMed ID: 28331027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presentation of a PTHrP-secreting pancreatic neuroendocrine tumour, with hypercalcaemic crisis, pre-eclampsia, and renal failure.
    Abraham P; Ralston SH; Hewison M; Fraser WD; Bevan JS
    Postgrad Med J; 2002 Dec; 78(926):752-3. PubMed ID: 12509695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas.
    Pavel ME; Hassler G; Baum U; Hahn EG; Lohmann T; Schuppan D
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):434-43. PubMed ID: 15807874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin receptor expression in a parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumour causing severe hypercalcaemia.
    Müssig K; Petersenn S; Wehrmann M; Horger M; Vierling P; Häring HU; Gallwitz B
    Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):719-23. PubMed ID: 17625444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Denosumab normalized plasma calcium concentration in malignancy-associated hypercalcaemia].
    Størling L; Villadsen GE; Krogh K; Vestergaard P
    Ugeskr Laeger; 2014 Jul; 176(30):. PubMed ID: 25292242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral hypercalcemia of malignancy (pseudohyperparathyroidism).
    Peter SA
    N Y State J Med; 1985 Jun; 85(6):242. PubMed ID: 3860751
    [No Abstract]   [Full Text] [Related]  

  • 19. Watery diarrhoea syndrome with episodic hypercalcaemia.
    Holdaway IM; Evans MC; Clarke ED
    Aust N Z J Med; 1977 Feb; 7(1):63-5. PubMed ID: 194562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours.
    Oberg K
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S17-25. PubMed ID: 22005113
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.